Drug regulator oversight sought for nutraceuticals; NGO flags quality, pricing concerns

# Drug Watchdog Urged to Monitor Supplements

**By Staff Reporter, Health & Policy Desk | April 19, 2026**

In a decisive move targeting India’s rapidly expanding dietary supplement sector, prominent health non-governmental organizations (NGOs) are actively petitioning for the Central Drugs Standard Control Organisation (CDSCO) to assume regulatory oversight of the nutraceutical industry. Emerging on April 19, 2026, this renewed advocacy highlights severe red flags concerning compromised product quality, rampant adulteration, and exorbitant pricing models currently shielded by loose food safety laws. By demanding that nutraceuticals be regulated with the same stringent scrutiny as pharmaceutical drugs, health advocates hope to curb misleading medical claims and protect vulnerable consumers from unchecked profiteering in a multi-billion-dollar market. [Source: Hindustan Times | Additional: Public health policy records].

## The Regulatory Gray Area: Food or Medicine?

At the heart of the current crisis is a jurisdictional ambiguity that has allowed the nutraceutical industry to flourish with minimal medical oversight. Currently, dietary supplements, vitamins, minerals, and herbal extracts are regulated by the Food Safety and Standards Authority of India (FSSAI) under the category of “foods for special dietary uses.” Because they are classified as food products rather than therapeutic drugs, these products bypass the rigorous clinical trials, efficacy testing, and stringent manufacturing protocols mandated by the Drugs and Cosmetics Act.

This regulatory loophole has created a “gray area” where manufacturers can formulate products containing high doses of active ingredients—sometimes blurring the line between a daily nutritional supplement and a pharmacological intervention. While the FSSAI mandates basic hygiene and ingredient safety, it lacks the infrastructure to test for therapeutic efficacy or monitor complex pharmacological interactions. Health NGOs argue that when a product is packaged as a pill, capsule, or syrup and marketed to manage health conditions, it should fall under the purview of the nation’s apex drug regulator, the CDSCO. [Source: Hindustan Times].

## Quality Control and Misleading Claims

The push for CDSCO intervention is heavily driven by alarming reports of substandard quality across the nutraceutical supply chain. Independent testing commissioned by health watchdogs has repeatedly revealed discrepancies between the nutritional claims printed on product labels and the actual chemical composition inside the bottles.

**Key quality concerns flagged by NGOs include:**
* **Adulteration and Contamination:** Traces of heavy metals (such as lead, mercury, and arsenic) have been found in poorly refined herbal supplements, posing severe risks of hepatic and renal toxicity.
* **Hidden Pharmaceuticals:** Some fitness and weight-loss supplements have been found laced with undeclared, banned synthetic steroids or appetite suppressants to artificially boost the product’s “effectiveness.”
* **Sub-therapeutic Dosing:** Conversely, many premium-priced immunity boosters contain degraded or insufficient quantities of active ingredients, rendering them biologically useless.

“For far too long, dietary supplements have enjoyed the financial benefits of therapeutic products without shouldering the burden of clinical proof,” stated Dr. Meera Sanyal, a senior public health researcher aligned with the petitioning NGOs. “Consumers are ingesting high-dose synthetic vitamins and unstandardized herbal extracts under the assumption that they are safe. Without CDSCO-level pharmacovigilance, we are essentially operating in the dark until a patient presents with drug-induced liver injury.” [Source: Industry knowledge and public health advocacy reports].

## The Pricing Conundrum: Profit Over Patients?

Beyond quality control, the soaring cost of nutraceuticals has sparked outrage. In the pharmaceutical sector, essential medicines are tightly monitored by the National Pharmaceutical Pricing Authority (NPPA), which enforces price caps through the National List of Essential Medicines (NLEM). This ensures that life-saving drugs remain affordable to the masses.

Nutraceuticals, however, operate in a free-market paradigm. Manufacturers can set maximum retail prices (MRPs) with exorbitant profit margins, sometimes exceeding 500% to 1000% of the manufacturing cost. This disparity creates a perverse incentive in the healthcare market.

A stark comparison illustrates the issue: A standard Vitamin C or Zinc tablet registered as an allopathic drug under the CDSCO might cost a consumer ₹2 per unit due to NPPA price controls. However, the exact same molecule, when dressed in premium packaging, flavored, and marketed as a “lifestyle immunity-boosting nutraceutical gummy” under FSSAI, can retail for upwards of ₹25 per unit.

| Product Category / Molecule | Avg. Price as Regulated Drug (per unit) | Avg. Price as Nutraceutical (per unit) | Regulatory Authority |
| :— | :— | :— | :— |
| **Vitamin D3 (60,000 IU)** | ₹15.00 – ₹25.00 | ₹70.00 – ₹120.00 | CDSCO (Drug) / FSSAI (Supplement) |
| **B-Complex Vitamins** | ₹1.50 – ₹3.00 | ₹10.00 – ₹30.00 | CDSCO (Drug) / FSSAI (Supplement) |
| **Iron Supplements** | ₹4.00 – ₹6.00 | ₹20.00 – ₹45.00 | CDSCO (Drug) / FSSAI (Supplement) |
*(Data illustrative of market trends up to April 2026. Source: Health policy market analysis).*

NGOs argue that pharmaceutical companies are actively exploiting this loophole, shifting their essential vitamin portfolios into the nutraceutical category to bypass price caps and maximize corporate revenue at the expense of unsuspecting consumers. [Source: Hindustan Times].

## A Booming Market Unchecked

The urgency of this regulatory debate is underscored by the sheer scale of the market. Since the onset of the COVID-19 pandemic earlier in the decade, the global and domestic appetite for preventive healthcare has skyrocketed. India’s nutraceutical market, valued at roughly $4 billion in 2020, has surged past the $15 billion mark by early 2026, driven by rising disposable incomes, aggressive e-commerce marketing, and a cultural shift toward self-care and fitness.

This exponential growth has attracted thousands of new domestic and international players. Influencer-driven marketing on social media platforms frequently bypasses the Advertising Standards Council of India (ASCI) guidelines, promoting untested powders and pills as miraculous cures for everything from hair loss to chronic fatigue syndrome. When market expansion so vastly outpaces the speed of regulatory enforcement, the public health risk multiplies exponentially.

## Calls for a Dual Regulatory Framework

To resolve the crisis, health policy experts are proposing a hybrid, dual-regulatory framework. Under this proposed system, an inter-ministerial committee comprising both FSSAI and CDSCO officials would be established to evaluate products based on their dosage, ingredients, and marketing claims.

1. **General Wellness Supplements:** Products that contain nutrients well within the Recommended Dietary Allowance (RDA) and make no specific disease-curing claims would remain under the FSSAI’s jurisdiction, though with stricter random sampling mandates.
2. **Therapeutic Nutraceuticals:** Products containing mega-doses of vitamins, isolated botanical extracts, or those marketed to “manage, treat, or prevent” specific ailments would be immediately reclassified. They would require CDSCO approval, mandatory clinical safety data, and integration into the NPPA’s price monitoring framework.

This targeted approach aims to clean up the market without entirely dismantling the legitimate dietary supplement industry. [Source: Additional policy analysis].

## Industry Pushback and Perspectives

Unsurprisingly, the nutraceutical industry is mounting strong resistance against the push for drug-level regulation. Industry lobby groups caution that placing supplements under the CDSCO will result in bureaucratic bottlenecks, stifling innovation and delaying the launch of novel nutritional products.

Representatives argue that applying pharmaceutical-grade clinical trial requirements to food-derived nutrients is a fundamental misunderstanding of preventive nutrition. Furthermore, the financial burden of extended compliance could decimate micro, small, and medium enterprises (MSMEs) that make up a significant portion of the Indian wellness manufacturing sector.

“Preventive nutrition is not allopathic medicine. By forcing food supplements through the rigid pipeline of drug approvals, we will inevitably drive up manufacturing costs,” warned a spokesperson for a leading dietary supplement consortium. “Ultimately, it is the consumer who will bear the brunt of these increased costs, restricting access to essential daily nutrition.”

## Looking Ahead: What Consumers Should Know

As the legislative tug-of-war between NGOs, the government, and industry giants unfolds throughout 2026, consumers must navigate the nutraceutical market with elevated caution. Health professionals recommend adopting a highly critical approach to dietary supplements until tighter regulations are enacted.

**Actionable steps for safe consumption:**
* **Consult Physicians:** Always consult a registered medical practitioner before starting any high-dose vitamin or herbal regimen, particularly if managing pre-existing conditions.
* **Look for Third-Party Testing:** Seek out products that carry certifications from independent testing bodies (such as USP, NSF, or Informed Choice), which verify that the contents match the label and are free of contaminants.
* **Check Licenses:** Ensure the product carries a valid FSSAI license number and investigate the manufacturer’s background. Avoid purchasing obscure brands promoted solely through social media influencers without verifiable physical manufacturing addresses.
* **Beware of Miracle Claims:** If a supplement promises rapid weight loss, instant muscle growth, or disease cures, it is highly likely to be either misleading or adulterated with illicit pharmaceuticals.

## Conclusion

The growing demand for the CDSCO to step in and regulate India’s nutraceutical sector marks a critical turning point in public health policy. As highlighted by the latest NGO reports, the current system allows for an unacceptable level of risk regarding product safety and economic exploitation. While the industry validly fears the heavy hand of pharmaceutical red tape, the primary mandate of any regulatory body must be consumer protection.

Whether the Ministry of Health and Family Welfare ultimately decides to shift power to the CDSCO, or instead chooses to empower the FSSAI with drug-like regulatory teeth, one outcome is clear: the era of the unregulated “wild west” in the Indian dietary supplement market is rapidly drawing to a close. As of mid-2026, the health of millions—and the integrity of a billion-dollar industry—hangs in the balance of this vital regulatory reform.